Articles dans des revues avec comité de lecture (67)
  1. 33. Dimova, T., Brouwer, M., Gosselin, F., Tassignon, J., Leo, O., donner, C., Marchant, A., & Vermijlen, D. (2015). Effector Vγ9Vδ2 T cells dominate the human fetal γδ T-cell repertoire. Proceedings of the National Academy of Sciences of the United States of America, 112(6), E556-E565. doi:10.1073/pnas.1412058112/-/DCSupplemental
  2. 34. Khairallah, C., Netzer, S., Villacreces, A., Juzan, M., Rousseau, B., Dulanto Magallanes, S. A., Giese, A., Costet, P., Praloran, V., Moreau, J. F., Dubus, P., Vermijlen, D., Dechanet-Merville, J., & Capone, M. (2015). γδ T Cells Confer Protection against Murine Cytomegalovirus (MCMV). P L o S Pathogens, 11(3), e1004702, 1-22. doi:10.1371/journal.ppat.1004702
  3. 35. Vermijlen, D., Braun, M. Y., & Marchant, A. (2014). Do PI3-kinase mutations drive T cells insane? Cellular & Molecular Immunology, 11(4), 320-322. doi:10.1038/cmi.2014.11
  4. 36. Huygens, A., Dauby, N., Vermijlen, D., & Marchant, A. (2014). Immunity to cytomegalovirus in early life. Frontiers in immunology, 5, 552. doi:10.3389/fimmu.2014.00552
  5. 37. Vermijlen, D., & Prinz, I. (2014). Ontogeny of Innate T Lymphocytes - Some Innate Lymphocytes are More Innate than Others. Frontiers in immunology, 5, 486. doi:10.3389/fimmu.2014.00486
  6. 38. Scheper, W., van Dorp, S., Kersting, S., Pietersma, F., Lindemans, C., Hol, S., Heijhuurs, S., Sebestyen, Z., Gründer, C., Marcu-Malina, V., Marchant, A., donner, C., Plachter, B., Vermijlen, D., van Baarle, D., & Kuball, J. (2013). γδT cells elicited by CMV reactivation after allo-SCT cross-recognize CMV and leukemia. Leukemia, 27(6), 1328-1338. doi:10.1038/leu.2012.374
  7. 39. Moens, E., Brouwer, M., Dimova, T., Goldman, M., Willems, F., & Vermijlen, D. (2011). IL-23R and TCR signaling drives the generation of neonatal Vgamma9Vdelta2 T cells expressing high levels of cytotoxic mediators and producing IFN-gamma and IL-17. Journal of leukocyte biology, 89(5), 743-752. doi:10.1189/jlb.0910501
  8. 40. Meraviglia, S., Eberl, M., Vermijlen, D., Todaro, M., Buccheri, S., Cicero, G., La Mendola, C., Guggino, G., D'Asaro, M., Orlando, V., Scarpa, F., Roberts, A., Caccamo, N., Stassi, G., Dieli, F., & Hayday, A. C. (2010). In vivo manipulation of Vgamma9Vdelta2 T cells with zoledronate and low-dose interleukin-2 for immunotherapy of advanced breast cancer patients. Clinical and experimental immunology, 161(2), 290-297. doi:10.1111/j.1365-2249.2010.04167.x
  9. 41. Vermijlen, D., Brouwer, M., donner, C., Liesnard, C., Tackoen, M., Van Rysselberge, M., Twite, N., Goldman, M., Marchant, A., & Willems, F. (2010). Human cytomegalovirus elicits fetal gammadelta T cell responses in utero. The Journal of experimental medicine, 207(4), 807-821. doi:10.1084/jem.20090348
  10. 42. Van Coppernolle, S., Verstichel, G., Timmermans, F., Velghe, I., Vermijlen, D., De Smedt, M., Leclercq, G., Plum, J., Taghon, T., Vandekerckhove, B., & Kerre, T. (2009). Functionally mature CD4 and CD8 TCRalphabeta cells are generated in OP9-DL1 cultures from human CD34+ hematopoietic cells. The Journal of immunology, 183(8), 4859-4870. doi:10.4049/jimmunol.0900714
  11. 43. Dieli, F., Vermijlen, D., Fulfaro, F., Caccamo, N., Meraviglia, S., Cicero, G., Roberts, A., Buccheri, S., D'Asaro, M., Gebbia, N., Salerno, A., Eberl, M., & Hayday, A. C. (2007). Targeting human {gamma}delta} T cells with zoledronate and interleukin-2 for immunotherapy of hormone-refractory prostate cancer. Cancer research, 67(15), 7450-7457. doi:10.1158/0008-5472.CAN-07-0199
  12. 44. Vermijlen, D., Ellis, P., Langford, C., Klein, A., Engel, R., Willimann, K., Jomaa, H., Hayday, A. C., & Eberl, M. (2007). Distinct cytokine-driven responses of activated blood gammadelta T cells: insights into unconventional T cell pleiotropy. The Journal of immunology, 178(7), 4304-4314.
    13. << Précédent 1 2 3 4 5 6 7 8 9 10 Suivant >>